ArticleSelf/nonself2010
Immunopathogenesis of inflammatory bowel disease.
Article in Self/nonself, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 232 citations in OpenAlex.
- Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact?Acta bio-medica : Atenei Parmensis · 2018Pooled it
- Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.Journal of clinical pharmacology · 2016Trial
- Therapeutic Effects of Aqueous Infusion of Cotinus coggygria Scop Leaves on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice.Chinese journal of integrative medicine · 2026Article
- T cell and cytokine signatures as early predictors of response to IL-12/IL-23 inhibition in Crohn's disease.Frontiers in immunology · 2026Article
- Article
- Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Review
- Genome-scale metabolic model-guided systematic framework for designing customized live biotherapeutic products.NPJ systems biology and applications · 2025Review
- Article
- Synergistic Anti-Inflammatory Effects of Pomegranate Peel-Hawthorn Combinations in Ulcerative Colitis: Network Pharmacology Prediction and Experimental Validation.Current issues in molecular biology · 2025Article
- Tocilizumab unfolds colo-protective and immunomodulatory effect in experimentally induced ulcerative colitis via mitigating autophagy and ER stress signaling.Inflammopharmacology · 2024Article
- A Versatile Intestine-on-Chip System for Deciphering the Immunopathogenesis of Inflammatory Bowel Disease.Advanced healthcare materials · 2024Article
- Causal relationship between gutThe EPMA journal · 2023Article
- APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease.Biomolecules · 2023Review
- Crohn's Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review.Life (Basel, Switzerland) · 2023Review
- Inflammatory Bowel Diseases: An Updated Overview on the Heat Shock Protein Involvement.International journal of molecular sciences · 2023Review
- Interplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases.The Journal of nutritional biochemistry · 2023Review
- Therapy Used to Promote Disease Remission Targeting Gut Dysbiosis, in UC Patients with Active Disease.Journal of clinical medicine · 2022Review
- Review
- Therapeutic Efficacy of Novel HDAC Inhibitors SPA3052 and SPA3074 against Intestinal Inflammation in a Murine Model of Colitis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Gut microbiota-stem cell niche crosstalk: A new territory for maintaining intestinal homeostasis.iMeta · 2022Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a group of idiopathic, chronic and relapsing inflammatory conditions of the gastrointestinal tract. Familial and epidemiological studies have stressed the involvement of genetic factors and have also shown the critical role of environmental factors such as sanitation and hygiene in the development of IBD. However, the molecular mechanisms of intestinal inflammation in IBD have long remained unknown. In recent years, the study of susceptibility genes involved in the detection of bacterial components and in the regulation of the host immune response has shed light onto the potential role of intestinal pathogens and gut flora in IBD immunobiology. This review presents current knowledge on intestinal epithelial barrier alterations and on dysfunction of mucosal innate and acquired immune responses in IBD. The data support the etiological hypothesis which argues that pathogenic intestinal bacteria and/or infectious agents initiate and perpetuate the inflammation of the gut through disruption of tolerance towards the commensal microbiota in an individual with genetic vulnerability.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.